Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurr
PUBLISHED: 2015-11-26  526 total views, 1 today

Scott Antonia1, Johanna Bendell2,Matthew Taylor3, Emiliano Calvo4Dirk Jäger5, Filippo De braud6, Patricka. Ott7, M. catherine Pietanza8Leora Horn9, Dung t. Le10, Michaela. Morse11, José a. López-martin12Paolo a. Ascierto13, Olaf Christensen14, Josephf. Grosso14, Jason Simon14Chen-sheng Lin14, Joseph paul Eder15


1Thoracic OncologyDepartment, H. Lee Moffitt Cancer Center & Research Institute, 2PLLC, Sarah CannonResearch Institute/Tennessee Oncology, 3Oregon Health &Science University, 4Centro IntegralOncológico Clara Campa, START Madrid, 5Heidelberg UniversityHospital, 6Istituto Nazionale deiTumori, 7Dana-Farber CancerInstitute, 8Memorial Sloan KetteringCancer Center, 9Vanderbilt-Ingram CancerCenter, 10The Sidney KimmelComprehensive Cancer Center at Johns Hopkins, 11Duke University MedicalCenter, 12‘12 de Octubre’University Hospital and Research Institute, 13Istituto NazionaleTumori Fondazione Pascale, 14Bristol-MyersSquibb, 15Yale Cancer Center


Objective:Patients (pts) with SCLC respond toinitial platinum (PLT) based chemotherapy (CT), but rapidly progress. Combinedblockade of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4(CTLA-4) immune checkpoint pathways has anti-tumor activity with a manageablesafety profile. Nivolumab (nivo) is a fully human IgG4 PD-1 immune checkpointinhibitor approved in the EU, US, & Japan. Interim efficacy and safety ofnivo +/- ipilimumab (ipi), a CTLA-4 checkpoint inhibitor, in pretreated SCLCpts are reported. 

Method: PLT sensitive or refractory pts withprogressive disease (PD) were enrolled regardless of tumor PD-L1 status ornumber of prior CT treatments (tx), and randomized to nivo 3mg/kg IV Q2W ornivo+ipi (1+1mg/kg or 1+3mg/kg) IV Q3W for 4 cycles followed by nivo 3mg/kgQ2W. Primary objective was ORR. Other objectives were safety, PFS, OS, andbiomarker analysis. 

Result: Of 90 pts enrolled (nivo, n=40; nivo+ipi,n=50 [nivo1+ipi1, n=3; nivo1+ipi3, n=47]); 53% had ≥2 prior tx.Treatment-related adverse events (TRAEs) in ≥10% were fatigue (18%), diarrhea(13%), nausea (10%), and decreased appetite (10%) with nivo; diarrhea (23%),fatigue (21%), rash (21%), pruritus (19%), hypothyroidism (15%), nausea,hyperthyroidism and maculopapular rash (13% each), and increased lipase (11%)with nivo1+ipi3. Grade 3–4 TRAEs in ≥5% included diarrhea (9%) and increasedlipase (6%) with nivo1+ipi3. Pneumonitis occurred in 2 pts in nivo (grade 1–2)and 1 pt in nivo1+ipi3 (grade 3–4). One pt in the nivo1+ipi 3 arm experiencedfatal myasthenia gravis. Of 40 evaluable nivo pts, 18% experienced PR (medianduration of ongoing responses [mDOR] not reached [range 4.1–11+ mo]); 20% SD;and 53% PD. Of 46 evaluable nivo+ipi pts, 2% experienced CR; 15% PR (mDOR 6.9mo [range 1.5–11.1+ mo]); 37% SD, and 37% PD. Seven pts in the nivo+ipi armexperienced PR after database lock; 4 pts in the nivo+ipi arm did not reachfirst tumor assessment. 20% pts continue treatment with nivo and 42% withnivo+ipi. 

Conclusion: In a PD-L1-unselected SCLC population withprogression post PLT-CT, nivo or nivo+ipi was tolerable. ORR was 18% (nivo) and17% (nivo+ipi); durable responses were noted. Updated safety, clinicalactivity, and biomarker analysis will be presented.Clinical Trial Number:NCT1928394.


Key Words: nivolumab  ipilimumab small cell lung cancer

Copyright © 1998 - 2019 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us

Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)